Crunching the numbers. Responsibly.
BACKGROUND: Berotralstat is a once-daily oral medication for the prophylaxis of hereditary angioedema (HAE) attacks in patients aged 12 years and older. OBJECTIVE: To assess the long-term safety and efficacy of berotralstat in patients with HAE caused by C1 inhibitor deficiency. METHODS: APeX-S was a global, open-label phase 2 study (NCT03472040) assessing berotralstat 150 and 110 mg for up to 96 weeks in the United States and 240 weeks elsewhere. The primary objective was long-term safety and tolerability; secondary objectives included efficacy and impact on quality of life (QoL) of berotralstat. Safety was evaluated by means of treatment-emergent adverse events and laboratory analyses. Efficacy was assessed using the number and rate of HAE attacks, durability of response, and number and proportion of days with angioedema symptoms. QoL was evaluated using the Angioedema Quality of Life Questionnaire. RESULTS: In APeX-S, 387 patients were enrolled and received berotralstat 150 mg (n = 287) or 110 mg (n = 100) from day 1. A total of 70 patients on berotralstat 110 mg crossed over to berotralstat 150 mg after a median (range) of 48 (46-71) weeks. Treatment-emergent adverse events up to 240 weeks were reported by 334 patients (86.3%); the most common being nasopharyngitis (23.8%), headache (14.7%), diarrhea (14.5%), upper respiratory tract infection (12.9%), and abdominal pain (11.1%). Treatment with berotralstat led to improvements in HAE attack rates and Angioedema Quality of Life Questionnaire scores up to week 96, with greater improvements observed in patients who received berotralstat 150 mg from day 1. CONCLUSION: This study supports the long-term safety of berotralstat and its efficacy in preventing HAE attacks and improving QoL. CLINICAL TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov as NCT03472040 (https://clinicaltrials.gov/study/NCT03472040).
This study supports the long-term safety of berotralstat and its efficacy in preventing HAE attacks and improving QoL.
preventive efficacy is not independently identified without a comparator or prospective attack-rate baseline
Treatment with berotralstat led to improvements in HAE attack rates and Angioedema Quality of Life Questionnaire scores up to week 96.
open-label longitudinal trends are vulnerable to attrition, expectation effects, and absent prospective attack-rate baseline
Treatment-emergent adverse events up to 240 weeks were reported by 334 patients (86.3%).
directly reported descriptive incidence is consistent across the abstract, Results, and Table 2
Derived from the full evaluation — not a separate score.
Strengths
The study enrolled 387 patients at 86 sites across 22 countries and reports adverse events for up to 240 weeks, materially extending the interim analysis.
↳ Results, Patients and Safety; Discussion, comparison with interim analysis
TEAEs, serious and grade 3 or 4 events, discontinuations, and laboratory abnormalities are reported by treatment group, including focused discussion of ALT elevations after androgen discontinuation.
↳ Table 2; eTables 1–7; Results, Safety
The Discussion explicitly connects nonrandom allocation to regional and prior-treatment imbalances and states that absent baseline rates and placebo control prevent assessment of pretreatment attack-rate change.
↳ Discussion, limitations paragraph
Limitations
No placebo group or prospective baseline attack-rate period was included, so declining on-treatment attack rates cannot independently identify a preventive treatment effect.
↳ Methods, Objectives and End Points; Discussion, limitations
Only 125 patients remained beyond 96 weeks, while discontinuations reflected commercial access, perceived lack of efficacy, adverse events, and consent withdrawal without a formal retention-bias analysis.
↳ Results, Patients; Figure 2
The conclusion says the study supports efficacy in preventing attacks, despite the paper's acknowledgment that it is noncomparative and lacks prospectively collected baseline attack rates.
↳ Abstract, Conclusion; Discussion, limitations and final paragraph
The principal contribution is the enlarged 387-patient safety dataset with follow-up extending to 240 weeks, supported by detailed adverse-event and laboratory tables. The efficacy analysis is descriptive, with no placebo group, no prospective attack-rate baseline, mostly nonrandom dose allocation, and substantial changes in the retained cohort over time. Those limitations make observed attack-rate and QoL trends informative but insufficient to establish preventive efficacy from this study alone. The paper otherwise presents its methods, numerical results, prior-trial comparisons, and disclosed limitations clearly.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.8
Confidence highThe final analysis expands the interim cohort from 227 to 387 patients and extends safety reporting to 240 weeks, providing a real long-term descriptive increment. It confirms an established profile rather than answering a new comparative or mechanistic question.
“Here, we report safety data up to week 240 and efficacy data up to week 96.”
Detailed adverse-event categories, laboratory outcomes, attack definitions, and patient disposition support descriptive safety reporting. Preventive efficacy is not independently identifiable because allocation was mostly nonrandom, no placebo or prospective attack-rate baseline was available, and attrition was not formally analyzed for selection bias.
“As a result, changes in attack rates from before berotralstat initiation could not be assessed.”
The paper proceeds clearly from design and patient disposition through safety, efficacy, QoL, and limitations, with consistent tables and figures. The phrase “efficacy in preventing HAE attacks” materially overstates what this noncomparative dataset alone establishes.
“This study supports the long-term safety of berotralstat and its efficacy in preventing HAE attacks.”
The Discussion quantitatively compares the final results with APeX-2, APeX-J, and the earlier APeX-S analysis and links key limitations to their consequences. Contextual coverage is strongest within the berotralstat development program and less comprehensive for independent long-term evidence on competing prophylactic therapies.
“The total number of patients in APeX-S was also increased from 227 in the interim analysis to 387.”
Lower confidence on Methodological Rigour, Positioning — domain match limited.
Caveats4 of 4 checks
Reported counts and study-flow details are internally consistent, but the efficacy conclusion is stronger than the study's uncontrolled longitudinal evidence independently supports.
Ethics approval, consent, registration, funding, and conflicts are declared. The manufacturer participated in study design and data analysis and interpretation, which is a disclosed interpretive watch-out rather than evidence of misconduct.
Flags: 3 declared / 5 total
31 of 32 checkable references verified
35 references in manuscript 3 are books, websites or datasets — counted, but not index-checkable
No retraction notice found in Retraction Watch.
Sources: Retraction Watch ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
Berotralstat is already approved and used across multiple jurisdictions, so the findings can immediately support deployment rather than requiring preclinical or implementation translation. The report does not provide comparative implementation guidance.
“Berotralstat is approved in the United States, the European Union/European Economic Area, the United Kingdom, Japan, Canada, Switzerland, and other markets.”
AI-generated, human-governed. Something look off? Contact us to request a review.